BioCentury | Mar 19, 2021
Product Development

Point’s SPAC, Aktis’ A round add to cash flow for radiotherapies: Data Byte

...funding.Excitement for radiopharmaceuticals has created opportunities for companies to raise growing rounds in quick succession. Fusion Pharmaceuticals Inc. raised...
...Nordic Nanovector ASA (OSE:NANOV) raised $53 million on the public markets. Karen Tkach Tuzman Point Biopharma Inc. Aktis Oncology Fusion Pharmaceuticals Inc. RayzeBio...
BioCentury | Dec 11, 2020
Finance

AbCellera valuation tops $15B as 2020’s IPO class nears completion

...the $253 million offering by Repare Therapeutics Inc. (NASDAQ:RPTX) and the $212.5 million listing by Fusion Pharmaceuticals Inc....
BioCentury | Oct 15, 2020
Emerging Company Profile

RayzeBio pulling together radiotherapy platform with $45 million

...in Phase III testing for bone marrow transplant conditioning. Fusion Pharmaceuticals Inc....
BioCentury | Jun 26, 2020
Finance

Akouos’ first-day pop outshines peers among NASDAQ IPO trio

...to treat hearing loss caused by mutations in the OTOF gene (see “Sound Story” ). Fusion Pharmaceuticals Inc....
...29. Targets IGF1R (CD221) - Insulin-like growth factor-1 receptor OTOF - Otoferlin Paul Bonanos, Associate Editor Akouos Inc. Fusion Pharmaceuticals Inc. PolyPid...
BioCentury | Jun 26, 2020
Finance

Poseida brings in $110M ahead of IPO as more biotechs line up for NASDAQ debuts

...are revisiting their IPO plans after snagging mezzanine rounds. Another pair -- Akouos Inc. and Fusion Pharmaceuticals Inc....
...cell immunoreceptor with Ig and ITIM domains Elizabeth S. Eaton, Staff Writer Poseida Therapeutics Inc. iTeos Therapeutics Inc. Akouos Inc. Fusion Pharmaceuticals Inc. Relay...
BioCentury | Jun 24, 2020
Finance

June 23 Quick Takes: Illumina selects first biotechs for U.K. accelerator; plus updates from the NASDAQ IPO queue, and venture rounds for Surrozen, Tara

...Amryt Pharma plc (LSE:AMYT; ISE:AYP) proposed to list and raise follow-on money on the exchange. Fusion Pharmaceuticals Inc....
...Beating Heart” ). Targets WNT - Wingless-type MMTV integration site family Elizabeth S. Eaton, Staff Writer Illumina Inc. Fusion Pharmaceuticals Inc. Akouos...
BioCentury | Jun 9, 2020
Finance

Next up on NASDAQ: trio of preclinical companies ready for debuts, plus new filings

...to $100 million: Akouos Inc., which is developing gene therapies for hearing loss; radiopharmaceuticals company Fusion Pharmaceuticals Inc....
...the Shanghai STAR board. Elizabeth S. Eaton, Staff Writer Generation Bio Co. Arya Sciences Acquisition Corp. Lantern Pharma Inc. Akouos Inc. Fusion Pharmaceuticals Inc. PolyPid...
BioCentury | Jun 6, 2020
Finance

Legend’s $424M NASDAQ offering pads 2020’s lead over prior years

...Kong stock exchange (see “IPO Queue Grows to 20 Life Sciences Companies” ). Akouos Inc., Fusion Pharmaceuticals Inc....
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

...discovery and development of therapies using its G protein-coupled receptor-targeted StaR platform. Cancer-focused radiopharmaceuticals company Fusion Pharmaceuticals Inc....
...Clinical Innovations LLC. Robin Sawka, BioCentury Staff Qiagen N.V. CytomX Therapeutics Inc. Recursion Pharmaceuticals Inc. 89bio Inc. Heptares Therapeutics Ltd. Sosei Group Corp. Fusion Pharmaceuticals Inc. Freeline...
BioCentury | Jan 17, 2020
Company News

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more

...imaging company Lantheus Holdings Inc. (NASDAQ:LNTH) hired Istvan Molnar as CMO. He was CMO at Fusion Pharmaceuticals Inc....
Items per page:
1 - 10 of 21
BioCentury | Mar 19, 2021
Product Development

Point’s SPAC, Aktis’ A round add to cash flow for radiotherapies: Data Byte

...funding.Excitement for radiopharmaceuticals has created opportunities for companies to raise growing rounds in quick succession. Fusion Pharmaceuticals Inc. raised...
...Nordic Nanovector ASA (OSE:NANOV) raised $53 million on the public markets. Karen Tkach Tuzman Point Biopharma Inc. Aktis Oncology Fusion Pharmaceuticals Inc. RayzeBio...
BioCentury | Dec 11, 2020
Finance

AbCellera valuation tops $15B as 2020’s IPO class nears completion

...the $253 million offering by Repare Therapeutics Inc. (NASDAQ:RPTX) and the $212.5 million listing by Fusion Pharmaceuticals Inc....
BioCentury | Oct 15, 2020
Emerging Company Profile

RayzeBio pulling together radiotherapy platform with $45 million

...in Phase III testing for bone marrow transplant conditioning. Fusion Pharmaceuticals Inc....
BioCentury | Jun 26, 2020
Finance

Akouos’ first-day pop outshines peers among NASDAQ IPO trio

...to treat hearing loss caused by mutations in the OTOF gene (see “Sound Story” ). Fusion Pharmaceuticals Inc....
...29. Targets IGF1R (CD221) - Insulin-like growth factor-1 receptor OTOF - Otoferlin Paul Bonanos, Associate Editor Akouos Inc. Fusion Pharmaceuticals Inc. PolyPid...
BioCentury | Jun 26, 2020
Finance

Poseida brings in $110M ahead of IPO as more biotechs line up for NASDAQ debuts

...are revisiting their IPO plans after snagging mezzanine rounds. Another pair -- Akouos Inc. and Fusion Pharmaceuticals Inc....
...cell immunoreceptor with Ig and ITIM domains Elizabeth S. Eaton, Staff Writer Poseida Therapeutics Inc. iTeos Therapeutics Inc. Akouos Inc. Fusion Pharmaceuticals Inc. Relay...
BioCentury | Jun 24, 2020
Finance

June 23 Quick Takes: Illumina selects first biotechs for U.K. accelerator; plus updates from the NASDAQ IPO queue, and venture rounds for Surrozen, Tara

...Amryt Pharma plc (LSE:AMYT; ISE:AYP) proposed to list and raise follow-on money on the exchange. Fusion Pharmaceuticals Inc....
...Beating Heart” ). Targets WNT - Wingless-type MMTV integration site family Elizabeth S. Eaton, Staff Writer Illumina Inc. Fusion Pharmaceuticals Inc. Akouos...
BioCentury | Jun 9, 2020
Finance

Next up on NASDAQ: trio of preclinical companies ready for debuts, plus new filings

...to $100 million: Akouos Inc., which is developing gene therapies for hearing loss; radiopharmaceuticals company Fusion Pharmaceuticals Inc....
...the Shanghai STAR board. Elizabeth S. Eaton, Staff Writer Generation Bio Co. Arya Sciences Acquisition Corp. Lantern Pharma Inc. Akouos Inc. Fusion Pharmaceuticals Inc. PolyPid...
BioCentury | Jun 6, 2020
Finance

Legend’s $424M NASDAQ offering pads 2020’s lead over prior years

...Kong stock exchange (see “IPO Queue Grows to 20 Life Sciences Companies” ). Akouos Inc., Fusion Pharmaceuticals Inc....
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

...discovery and development of therapies using its G protein-coupled receptor-targeted StaR platform. Cancer-focused radiopharmaceuticals company Fusion Pharmaceuticals Inc....
...Clinical Innovations LLC. Robin Sawka, BioCentury Staff Qiagen N.V. CytomX Therapeutics Inc. Recursion Pharmaceuticals Inc. 89bio Inc. Heptares Therapeutics Ltd. Sosei Group Corp. Fusion Pharmaceuticals Inc. Freeline...
BioCentury | Jan 17, 2020
Company News

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more

...imaging company Lantheus Holdings Inc. (NASDAQ:LNTH) hired Istvan Molnar as CMO. He was CMO at Fusion Pharmaceuticals Inc....
Items per page:
1 - 10 of 21